Testicular Cancer Surveillance

Testicular germ cell tumors are the most common solid malignancy in young men (ages 15-35), with cure rates exceeding 95% overall. Historically, after radical inguinal orchiectomy, all patients with clinical stage I disease underwent retroperitoneal lymph node dissection (RPLND) for seminoma and non-seminomatous germ cell tumors (NSGCT), or adjuvant radiation for seminoma. While effective, these adjuvant treatments carried significant morbidity: RPLND caused retrograde ejaculation in most patients (loss of antegrade ejaculation affecting fertility), and radiation carried long-term risks of secondary malignancy and cardiovascular disease. The recognition that 70-80% of stage I patients were already cured by orchiectomy alone—meaning adjuvant treatment was unnecessary overtreatment for the majority—prompted the development of surveillance strategies.

Large prospective surveillance cohorts from Princess Margaret Hospital (Toronto), Memorial Sloan Kettering, and the Danish Testicular Cancer Study Group demonstrated that surveillance after orchiectomy for stage I NSGCT was safe, with cancer-specific survival rates of 98-99% at 5 years. For stage I seminoma, relapse rates on surveillance were approximately 15-20%, with virtually all relapses cured by salvage chemotherapy or radiation. The MRC TE22 trial provided practice-changing evidence by randomizing stage I seminoma patients between single-agent carboplatin (one or two cycles) and adjuvant radiotherapy, showing equivalent relapse-free survival with reduced long-term toxicity for carboplatin. Critically, these studies established that the few patients who relapsed on surveillance could be successfully salvaged, maintaining the excellent overall survival while sparing the majority from unnecessary adjuvant treatment.

The Swedish and Norwegian Testicular Cancer Group (SWENOTECA) produced the largest prospective surveillance experience for both seminoma and NSGCT, with data on over 2000 patients demonstrating cancer-specific survival exceeding 99% with risk-adapted management. For stage I NSGCT, SWENOTECA showed that risk stratification by lymphovascular invasion (LVI) could identify a high-risk group (~50% relapse rate) suitable for one cycle of BEP chemotherapy, while the low-risk group (no LVI, ~15% relapse rate) could be safely observed. The reduction of CT frequency in surveillance protocols was a major advance—recognizing that the cumulative radiation from serial CTs posed its own cancer risk, protocols were revised to reduce the number of scans while maintaining detection sensitivity. The TRISST trial randomized seminoma surveillance patients to different imaging schedules and demonstrated that reduced-frequency CT with MRI was non-inferior, further decreasing radiation exposure.

All major guidelines now recommend surveillance as the preferred management for stage I seminoma and low-risk stage I NSGCT. The NCCN guidelines recommend active surveillance as the preferred approach for stage I seminoma, with single-dose carboplatin or radiation as alternatives. For stage I NSGCT, surveillance is preferred for low-risk (no LVI) disease; high-risk (LVI-positive) patients may be offered surveillance or 1 cycle of BEP chemotherapy. The EAU guidelines align with this approach and specifically recommend reduced CT frequency protocols (years 1-2 more intensive, then reduced), with consideration of MRI as an alternative to CT to reduce radiation exposure. ESMO guidelines similarly endorse surveillance as standard of care for both seminoma and NSGCT stage I, emphasizing the importance of risk stratification for NSGCT.

Surveillance is now the dominant management strategy for stage I testicular cancer, representing one of oncology's great de-escalation success stories. Over 80% of stage I seminoma patients and 60-70% of stage I NSGCT patients are managed with surveillance at major centers. The focus has shifted to optimizing surveillance protocols to minimize radiation exposure (fewer CTs, substituting MRI), reduce patient anxiety (streamlined visit schedules), and maintain the essentially 100% cancer-specific survival. Risk-adapted strategies using LVI for NSGCT allow tailoring of adjuvant therapy to the approximately 30% who are at highest risk of relapse. Primary RPLND is experiencing a limited resurgence for select NSGCT patients, driven by the use of minimally invasive robotic techniques that preserve ejaculatory function, though this remains institution-specific. Liquid biopsy approaches (serum microRNA-371a-3p) are showing promise as more sensitive and specific tumor markers than traditional AFP/HCG/LDH for detecting relapse during surveillance.